Results 11 to 20 of about 94,066 (344)

Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo. [PDF]

open access: goldJCI Insight, 2017
Huang XP   +9 more
europepmc   +3 more sources

Occurrence of Takotsubo Cardiomyopathy after Synthetic Cannabinoid Consumption [PDF]

open access: yesAddiction and Health, 2019
Background: Synthetic cannabinoid use such as “K2” and “Spice” is popular secondary to its inability to be detected in a urine drug screen. It is associated with a wide range of myocardial pathologies including obstructive and non-obstructive coronary ...
Denelle Mohammed
doaj   +1 more source

The DREADDful Hurdles and Opportunities of the Chronic Chemogenetic Toolbox

open access: yesCells, 2022
The chronic character of chemogenetics has been put forward as one of the assets of the technique, particularly in comparison to optogenetics. Yet, the vast majority of chemogenetic studies have focused on acute applications, while repeated, long-term ...
Marie Claes, Lies De Groef, Lieve Moons
doaj   +1 more source

Oneiroid catatonia due to the usage of spice: The case study

open access: yesEuropean Psychiatry, 2021
Introduction Designer drugs, as a term, first came about in the 1980s. Most of these “designer drugs” have synthetic cannabinoids and other psychoactive formulas difficulty to detect. Objectives A 28 year man was referred to the hospital.
O. Pityk   +4 more
doaj   +1 more source

Designer drugs: aspectos analíticos e biológicos

open access: yesQuímica Nova, 2012
In the recent years, analytical toxicologists have been facing difficulties in detecting designer drugs due to the chemical modifications on the existing structures and the speed in which they are released into the market, requiring the development and ...
Rachel Bulcão   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy